Cyclophosphamide–Based GVHD Prophylaxis Reduces Outcome Disparity in Transplants

CIBMTR shared a post on X about a recent paper.  .

Authors: Brian C. Shaffer, Mahasweta Gooptu, Todd E. DeFor, Martin Maiers, Javier Bolaños-Meade, Ramzi Abboud, Adrienne D. Briggs, Farhad Khimani, Dipenkumar Modi, Richard Newcomb, Elizabeth J. Shpall, Caitrin Bupp, Stephen R. Spellman, Heather E. Stefanski, Bronwen E. Shaw, Jeffery J. Auletta, Steven M. Devine, Antonio M. Jimenez Jimenez and Monzr M. Al Malki.

“Just published in Journal of Clinical Oncology: Post-Transplant Cyclophosphamide–Based Graft-Versus-Host Disease Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.”

Navneet Majhail shared the post, adding:

“Practice defining study, N>10K: ‘Use of PTCy results in comparable OS and GRFS using either MUD or MMUD HCT, expanding access to HCT for patients from all racial and ethnic ancestry groups’.” Prophylaxis Prophylaxis

Aaron Logan, Professor at UCSF Medical Center, shared comments about the paper as well:

“This is extremely important work supported by NMDP and CIBMTR. Use of MMUD with PTCy truly means there are donors for all! PTCy–Based GVHD Prophylaxis Attenuates Disparity in Outcomes Between Use of Matched or Mismatched Unrelated Donors.”

Source: CIBMTR/X, Navneet Majhail/X and Aaron Logan/X

Dr. Navneet Majhail, M.D., MS, FASTCT, is a board-certified hematologist and deputy physician-in-chief of blood cancers at the Sarah Cannon Transplant and Cellular Therapy Network. He is also the program medical director at the Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Medical Center in Nashville.

In his free time Dr. Majhail can be found on X/Twitter or enjoying time with his family and two goldendoodles.